Prevalence and Impact of Body Physical Changes in HIV Patients Treated with Highly Active Antiretroviral Therapy: Results from a Study on Patient and Physician Perceptions

被引:30
|
作者
Cabrero, Esther [1 ]
Griffa, Laura [1 ]
Burgos, Angel [1 ]
机构
[1] Abbott Labs, Dept Med, Madrid, Spain
关键词
REVERSE-TRANSCRIPTASE INHIBITORS; IMMUNODEFICIENCY-VIRUS-INFECTION; QUALITY-OF-LIFE; PROTEASE INHIBITORS; NAIVE PATIENTS; RISK-FACTORS; HIV-1-INFECTED PATIENTS; DERMATOLOGICAL FINDINGS; LIPODYSTROPHY SYNDROME; INSULIN-RESISTANCE;
D O I
10.1089/apc.2009.0191
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Patients infected with HIV treated with highly active antiretroviral therapy (HAART) frequently develop body physical changes (BPC) that have an important psychosocial burden. The purpose of this study was to determine the prevalence of BPC observed by HIV-infected patients and their attending physicians and to assess the impact BPC had on daily life. In this epidemiologic multicenter study, patients with HIV infection and their treating physicians filled out parallel questionnaires about their perceptions of specific BPC and their impact on daily activities. A total of 965 patient-physician questionnaires were collected across 98 health centers. Patient's mean age was 43.7 +/- 8.5 years and 72.6% were men. Adjusted prevalence of perceived BPC by patients and physicians was 55.1% (95% confidence interval [CI]: 52.0-58.1) and 55.2% (95% CI: 52.1-58.2), respectively (p = 1.000). Overall patient-physician agreement concerning perception of BPC was 83% (p < 0.0005). The most common BPC was lipoatrophy, described by 46.8% (95% CI: 43.7-49.8) of patients and 49.4% (95% CI: 46.3-52.5) of physicians (p = 0.033) followed by lipohypertrophy. No gender differences were observed in the global prevalence of BPC (p - 0.649). However, significantly more women reported lipoatrophy of the lower limbs (p - 0.009) and buttocks (p - 0.007), as well as lipohypertrophy (p 0.007), than men; 58.2% (95% CI: 54.0-62.4) patients noted that BPC negatively affected their daily activities. This study reflects the high prevalence of patient and physician-perceived BPC in the HIV population, and the adverse impact on daily life. Physicians should be aware of the psychosocial consequences of BPC in HIV patients in order to improve patient well-being.
引用
收藏
页码:5 / 13
页数:9
相关论文
共 42 条
  • [21] Prevalence of Hypertension in HIV/AIDS Patients on Highly Active Antiretroviral Therapy (HAART) Compared with HAART-Naive Patients at the Limbe Regional Hospital, Cameroon
    Dimala, Christian Akem
    Atashili, Julius
    Mbuagbaw, Josephine C.
    Wilfred, Akam
    Monekosso, Gottlieb L.
    PLOS ONE, 2016, 11 (02):
  • [22] Cardiovascular disease risk factors in HIV patients -: association with antiretroviral therapy.: Results from the DAD study
    Friis-Moller, N
    Weber, R
    Reiss, P
    Thiébaut, R
    Kirk, O
    Monforte, AD
    Pradier, C
    Morfeldt, L
    Mateu, S
    Law, M
    El-Sadr, W
    De Wit, S
    Sabin, CA
    Phillips, AN
    Lundgren, JD
    AIDS, 2003, 17 (08) : 1179 - 1193
  • [23] Recovery of Replication-Competent Residual HIV-1 from Plasma of a Patient Receiving Prolonged, Suppressive Highly Active Antiretroviral Therapy
    Sahu, Gautam K.
    Sarria, Juan C.
    Cloyd, Miles W.
    JOURNAL OF VIROLOGY, 2010, 84 (16) : 8348 - 8352
  • [24] Insulin resistance by homeostasis model assessment in HIV-infected patients on highly active antiretroviral therapy: cross-sectional study
    Guillen, Miguel A.
    Mejia, Fernando A.
    Villena, Jaime
    Turin, Christie G.
    Carcamo, Cesar P.
    Ticse, Ray
    DIABETOLOGY & METABOLIC SYNDROME, 2015, 7
  • [25] Insulin resistance by homeostasis model assessment in HIV-infected patients on highly active antiretroviral therapy: cross-sectional study
    Miguel A. Guillen
    Fernando A. Mejia
    Jaime Villena
    Christie G. Turin
    Cesar P. Carcamo
    Ray Ticse
    Diabetology & Metabolic Syndrome, 7
  • [26] Growth hormone improves lean body mass, physical performance, and quality of life in subjects with HIV-associated weight loss or wasting on highly active antiretroviral therapy
    Moyle, GJ
    Daar, ES
    Gertner, JM
    Kotler, DP
    Melchior, JC
    O'Brien, F
    Svanberg, E
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2004, 35 (04) : 367 - 375
  • [27] Effect of protease inhibitor-based highly active antiretroviral therapy on survival in HIV-associated advanced Kaposi's sarcoma patients treated with chemotherapy
    Leitch, H
    Trudeau, M
    Routy, JP
    HIV CLINICAL TRIALS, 2003, 4 (02): : 107 - 114
  • [28] Prevalence of dyslipidemia among HIV-infected patients using first-line highly active antiretroviral therapy in Southern Ethiopia: a cross-sectional comparative group study
    Tadewos, Agete
    Addis, Zelalem
    Ambachew, Henock
    Banerjee, Sandip
    AIDS RESEARCH AND THERAPY, 2012, 9
  • [29] Abacavir and risk of myocardial infarction in HIV-infected patients on highly active antiretroviral therapy: a population-based nationwide cohort study
    Obel, N.
    Farkas, D. K.
    Kronborg, G.
    Larsen, C. S.
    Pedersen, G.
    Riis, A.
    Pedersen, C.
    Gerstoft, J.
    Sorensen, H. T.
    HIV MEDICINE, 2010, 11 (02) : 130 - 136
  • [30] An open-label, prospective, observational study of the incidence of coronary artery disease in patients with HIV infection receiving highly active antiretroviral therapy
    Barbaro, G
    Di Lorenzo, G
    Cirelli, A
    Grisorio, B
    Lucchini, A
    Hazra, C
    Barbarini, G
    CLINICAL THERAPEUTICS, 2003, 25 (09) : 2405 - 2418